In a recent regulatory filing, details emerged regarding a transaction by Sheena Jonathan, who serves as a co-founder and director for the genetic testing firm Natera, Inc. (NASDAQ: NTRA). On May 1, 2026, Ms. Jonathan sold 107 shares of common stock at a price of $206.16 per share, resulting in a total transaction value of $22,059.
The sale was not an unscheduled market move but was executed according to a Rule 10b5-1(c) trading plan that had been established previously on January 31, 2025. The primary purpose for this specific transaction was to address tax withholding and remittance requirements that arose from the vesting of restricted stock units (RSUs).
Current Holdings and Ownership Structure
Following the execution of this sale, Ms. Jonathan maintains a direct holding of 255,652 shares of Natera common stock. This total includes 48 shares that were acquired through the company's 2015 Employee Stock Purchase Plan on April 30, 2026. Beyond her direct holdings, there are indirect interests involving two trusts: 20,282 shares held through the Caraluna 2 Trust and another 20,282 shares held through the Caraluna 1 Trust. However, it is noted that Ms. Jonathan disclaims beneficial ownership of those specific securities held within the trusts.
Operational Context and Recent Developments
Natera has recently been active across several operational and legal fronts. In terms of market sentiment and analysis, William Blair initiated coverage on the company with an Outperform rating, citing its robust standing within the diagnostics sector. This comes as the company navigates a significant legal outcome; a United States District Court in Delaware ruled in Natera's favor in a patent dispute against Invitae. The court decision grants Natera a 30% ongoing royalty related to certain product sales involving minimal residual disease.
The company has also focused on governance and scientific validation. On March 26, 2026, the board was expanded with the appointment of Eric Rubin, bringing the total number of board members to eleven. Scientifically, Natera's Signatera circulating tumor DNA assay has been the subject of research published in Nature Communications. The studies focused on anal and rectal cancer, indicating that patients who received negative tests via the Signatera assay demonstrated significantly improved survival rates.
Market Position and Insider Trends
While Natera's recent activity includes scientific and legal wins, some valuation metrics suggest caution. Analysis from InvestingPro indicates that Natera may be overvalued at its current price levels. Interestingly, despite individual sales for tax purposes, Barclays noted in an insider trading analysis that Natera stood out in the life sciences sector as one of the few companies where insiders were actively purchasing shares during the first quarter of 2026.